Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.95
(44.76%)
USD 43.95
(44.76%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.45 Billion JPY | -4.64% |
| 2022 | 14.1 Billion JPY | -12.04% |
| 2021 | 16.04 Billion JPY | 42.15% |
| 2020 | 11.28 Billion JPY | -11.51% |
| 2019 | 12.75 Billion JPY | 5831.16% |
| 2018 | 215 Million JPY | -36.01% |
| 2017 | 336 Million JPY | -47.91% |
| 2016 | 645 Million JPY | -12.24% |
| 2015 | 735 Million JPY | 243.46% |
| 2014 | 214 Million JPY | -8.15% |
| 2013 | 233 Million JPY | 0.0% |
| 2012 | - JPY | 0.0% |
| 2011 | - JPY | 0.0% |
| 2010 | - JPY | 0.0% |
| 2009 | - JPY | -100.0% |
| 2008 | 6 Million JPY | -85.71% |
| 2007 | 42 Million JPY | -72.19% |
| 2006 | 151 Million JPY | 0.0% |
| 2005 | - JPY | -100.0% |
| 2004 | 1 Billion JPY | -1.09% |
| 2003 | 1.01 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 6.58 Billion JPY | -3.9% |
| 2024 Q1 | 6.84 Billion JPY | -49.1% |
| 2023 Q1 | 8.15 Billion JPY | -42.17% |
| 2023 Q3 | 8.43 Billion JPY | 11.15% |
| 2023 Q2 | 7.58 Billion JPY | -7.0% |
| 2023 FY | 13.45 Billion JPY | -4.64% |
| 2023 Q4 | 13.45 Billion JPY | 59.53% |
| 2022 Q3 | 9.36 Billion JPY | 1.29% |
| 2022 Q4 | 14.1 Billion JPY | 50.64% |
| 2022 Q2 | 9.24 Billion JPY | -8.34% |
| 2022 Q1 | 10.08 Billion JPY | -37.11% |
| 2022 FY | 14.1 Billion JPY | -12.04% |
| 2021 FY | 16.04 Billion JPY | 42.15% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 Q2 | 4.73 Billion JPY | 0.0% |
| 2021 Q3 | 4.99 Billion JPY | 5.47% |
| 2021 Q4 | 16.04 Billion JPY | 221.25% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 FY | 11.28 Billion JPY | -11.51% |
| 2020 Q4 | 4.63 Billion JPY | 0.0% |
| 2019 Q1 | - JPY | -100.0% |
| 2019 FY | 12.75 Billion JPY | 5831.16% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 Q4 | 5.48 Billion JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2018 Q3 | 247 Million JPY | -12.1% |
| 2018 Q4 | 215 Million JPY | -12.96% |
| 2018 Q1 | 314 Million JPY | -6.55% |
| 2018 FY | 215 Million JPY | -36.01% |
| 2018 Q2 | 281 Million JPY | -10.51% |
| 2017 Q4 | 336 Million JPY | -8.94% |
| 2017 Q2 | 403 Million JPY | -34.04% |
| 2017 Q1 | 611 Million JPY | -5.27% |
| 2017 FY | 336 Million JPY | -47.91% |
| 2017 Q3 | 369 Million JPY | -8.44% |
| 2016 Q4 | 645 Million JPY | -1.53% |
| 2016 FY | 645 Million JPY | -12.24% |
| 2016 Q1 | 704 Million JPY | -4.22% |
| 2016 Q3 | 655 Million JPY | -3.68% |
| 2016 Q2 | 680 Million JPY | -3.41% |
| 2015 Q4 | 735 Million JPY | -3.16% |
| 2015 Q3 | 759 Million JPY | 268.45% |
| 2015 Q2 | 206 Million JPY | 0.49% |
| 2015 FY | 735 Million JPY | 243.46% |
| 2015 Q1 | 205 Million JPY | -4.21% |
| 2014 FY | 214 Million JPY | -8.15% |
| 2014 Q1 | 223 Million JPY | -4.29% |
| 2014 Q4 | 214 Million JPY | -2.73% |
| 2014 Q3 | 220 Million JPY | 1.38% |
| 2014 Q2 | 217 Million JPY | -2.69% |
| 2013 Q3 | 244 Million JPY | -3.94% |
| 2013 Q4 | 233 Million JPY | -4.51% |
| 2013 Q2 | 254 Million JPY | -0.78% |
| 2013 FY | 233 Million JPY | 0.0% |
| 2013 Q1 | 256 Million JPY | -0.39% |
| 2012 FY | - JPY | 0.0% |
| 2012 Q1 | - JPY | -100.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q4 | 257 Million JPY | 0.0% |
| 2011 FY | - JPY | 0.0% |
| 2011 Q4 | 192 Million JPY | 0.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2011 Q1 | - JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 FY | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 Q1 | - JPY | 0.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q2 | - JPY | 0.0% |
| 2009 Q1 | - JPY | 0.0% |
| 2009 FY | - JPY | -100.0% |
| 2008 FY | 6 Million JPY | -85.71% |
| 2007 FY | 42 Million JPY | -72.19% |
| 2006 FY | 151 Million JPY | 0.0% |
| 2005 FY | - JPY | -100.0% |
| 2004 FY | 1 Billion JPY | -1.09% |
| 2003 FY | 1.01 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | 52.924% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 67.55% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -13402.803% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -31731.839% |
| Novartis AG | 26.34 Billion USD | 48.934% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -33199.704% |